Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.

Search

43rd Annual Convention; Denver, CO; 2017

Event Details


Previous Page

 

B. F. Skinner Lecture Series Paper Session #478
CE Offered: PSY/BACB

Cannabis Dose-Effects Across Routes of Administration: Subjective, Performance, and Pharmacokinetic Differences

Monday, May 29, 2017
3:00 PM–3:50 PM
Convention Center Four Seasons Ballroom 4
Area: SCI; Domain: Basic Research
Instruction Level: Intermediate
CE Instructor: Christine E. Hughes, Ph.D.
Chair: Christine E. Hughes (University of North Carolina Wilmington)
RYAN VANDREY (Johns Hopkins University)
Dr. Vandrey is an experimental psychologist with degrees from the University of Delaware (BA) and University of Vermont (Ph.D.). He is currently an Associate Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU). Dr. Vandrey's research focuses on the behavioral pharmacology of cannabis (marijuana) with a primary focus of controlled laboratory studies with adult research volunteers, but also includes clinical trials, web-based survey research, and natural history studies with patient populations using cannabis/cannabinoids for therapeutic purposes. His work helped characterize the cannabis withdrawal syndrome, has provided novel data about the comparative pharmacokinetics and corresponding pharmacodynamics of cannabinoids across routes of administration, explored medications that are potential adjuncts to behavior therapy to improve rates of abstinence among individuals trying to quit using cannabis, examined the effects of cannabis on sleep, and provides information about the risks and benefits of medicinal use of cannabis/cannabinoids for various health conditions.
Abstract:

The use of cannabis (marijuana) for medical and non-medical purposes is expanding worldwide and now includes legal retail outlets for purchasing cannabis products in many areas. Retail cannabis products are varied with respect to dose and intended route of administration, yet the preponderance of scientific data is limited to analysis of the effects of smoked cannabis. This presentation will summarize data from a series of controlled human laboratory studies evaluating the dose effects of oral, smoked, and vaporized cannabis in healthy, non-tolerant individuals. Outcome measures to be described include subjective ratings of drug effects, cardiovascular measures, cannabinoid quantitation in biological fluid, and performance on psychomotor, memory, and divided attention tasks. Implications of the study findings will be discussed with respect to regulation of medical and non-medical cannabis products, drug testing, and education.

Target Audience:

Masters and Doctoral Level BCBAs

Learning Objectives: At the conclusion of the presentation, attendees will be able to: (1) Understand how route of administration alters the time course of cannabis effects; (2) Be able to describe adverse effects of cannabis that can occur at high doses; (3) Understand the relation between blood THC levels and behavioral effects.
 

BACK TO THE TOP

 

Back to Top
ValidatorError
  
Modifed by Eddie Soh
DONATE
{"isActive":false}